Stock Events

Stock Events

Arcutis Biotherapeutics 

$24
0
+$0.43+1.82% Thursday 04:00

Statistics

Day High
24.01
Day Low
24
52W High
-
52W Low
-
Volume
340
Avg. Volume
-
Mkt Cap
2.98B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19MayExpected
Q3 2025
Q4 2025
Next
-0.09
-0.02
0.06
0.13
Expected EPS
-0.053762
Actual EPS
N/A

Financials

-4.29%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
752.14MRevenue
-32.28MNet Income

Analyst Ratings

$34.00Average Price Target
The highest estimate is 36.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
83%
Hold
17%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ARQT.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie competes in the dermatology space with treatments like Skyrizi and Rinvoq, which can be direct competitors to Arcutis' dermatological products.
AMGEN
AMGN
Mkt Cap160.66B
Amgen has a strong presence in the treatment of psoriasis and other inflammatory diseases, directly competing with Arcutis' pipeline.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its Janssen Pharmaceuticals division, offers products like Stelara and Tremfya, competing in the psoriasis and dermatology market.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a portfolio of drugs for inflammatory conditions and dermatology, including Xeljanz, which competes in similar therapeutic areas as Arcutis.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline has a focus on dermatological conditions, including treatments for skin diseases, positioning it as a competitor.
Novartis
NVS
Mkt Cap237.61B
Novartis offers Cosentyx, a direct competitor in the psoriasis treatment market, challenging Arcutis' product offerings.
Merck
MRK
Mkt Cap214.76B
Merck has a diversified portfolio that includes treatments for inflammatory diseases, potentially competing with Arcutis in certain therapeutic areas.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb, with its range of anti-inflammatory and dermatology drugs, competes in the same space as Arcutis.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, known for Dupixent, competes in the dermatology and inflammatory disease market, directly challenging Arcutis' products.
Journey Medical
DERM
Mkt Cap213.64M
Journey Medical Corporation (formerly Dermira), focuses on dermatological conditions, making it a direct competitor in the dermatology space.

About

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Show more...
CEO
ISIN
US03969K1088

Listings

XNAS
US
ARQT
BOATS
BOATS
ARQT.BOATS

0 Comments

Share your thoughts

FAQ

What is Arcutis Biotherapeutics stock price today?▼
The current price of ARQT.BOATS is $24 USD — it has increased by +1.82% in the past 24 hours. Watch Arcutis Biotherapeutics stock price performance more closely on the chart.
What is Arcutis Biotherapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Arcutis Biotherapeutics stocks are traded under the ticker ARQT.BOATS.
What is Arcutis Biotherapeutics market cap?▼
Today Arcutis Biotherapeutics has the market capitalization of 2.98B
When is the next Arcutis Biotherapeutics earnings date?▼
Arcutis Biotherapeutics is going to release the next earnings report on May 19, 2026.
What were Arcutis Biotherapeutics earnings last quarter?▼
ARQT.BOATS earnings for the last quarter are 0.13 USD per share, whereas the estimation was 0.09 USD resulting in a +40.75% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Arcutis Biotherapeutics revenue for the last year?▼
Arcutis Biotherapeutics revenue for the last year amounts to 752.14M USD.
What is Arcutis Biotherapeutics net income for the last year?▼
ARQT.BOATS net income for the last year is -32.28M USD.
When did Arcutis Biotherapeutics complete a stock split?▼
Arcutis Biotherapeutics has not had any recent stock splits.